Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rebamipide - Otsuka Pharmaceutical

Next Previous
Drug Profile

Rebamipide - Otsuka Pharmaceutical

Alternative Names: MCT-SR; Mucosta; OPC-12759; OPC-12759E; OPC759; Pramipide; Proamipide

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Otsuka Pharmaceutical
  • Developer Kubota Vision; Otsuka Pharmaceutical
  • Class Amino acids; Anti-inflammatories; Antiulcers; Cytoprotectives; Eye disorder therapies; Quinolones; Small molecules
  • Mechanism of Action Oxygen radical formation antagonists; Oxygen radical scavengers; Prostaglandin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dry eyes; Gastric ulcer; Gastritis
  • Phase II Stomatitis
  • Discontinued Cancer; Diabetes mellitus; Keratoconjunctivitis; NSAID-induced ulcer; Ulcerative colitis; Xerostomia

Most Recent Events

  • 28 Aug 2022 No recent reports of development identified for phase-I development in Gastric-ulcer(In volunteers) in South Korea (PO, Controlled release)
  • 11 Mar 2021 Otsuka Pharmaceutical completes a phase III clinical trial in Gastritis (In adults, In the elderly) in South Korea (PO, Controlled release) (NCT04189705)
  • 01 Apr 2020 Acucela is now called Kubota Vision
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top